Market-Ready Probiotic Formulas for Women’s Health

Urinary tract infections (UTIs) are the most common bacterial infections in women, with up to 90% being caused by Escherichia coli bacteria. These bacteria can travel to the bladder, leading to cystitis.

Cystitis is usually treated with antibiotics; however, antibiotic treatment often fails to completely eradicate the infection due to bacterial biofilm formation. This can lead to persistent bacteriuria and recurring UTIs.

Probiotical offers many ready-to-market combinations of their probiotics with botanicals or synbiotics reducing the time to market as they have already completed the R&D and quality testing. One such formula is BIFICIST® , which combines specific probiotic strains, cranberry extract, and D-mannose. This combination offers a dual and synergistic mechanism of action at both urinary and intestinal levels, enhancing the management of recurrent UTIs.

BIFICIST®  contains Streptococcus thermophilus ST10, Lactiplantibacillus plantarum LP01, and Lacticaseibacillus paracasei LPC09, which offer specific activities against E. coli, anti-inflammatory properties, and protection and restoration of intestinal membrane integrity. LPC09 is also efficient in vitro at metabolizing oxalates, potentially offering protection from gut inflammation associated with prolonged supplementation with cranberry extract.